Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Eggert

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
European Journal of Clinical Pharmacology|August 1, 2013
Pharmacokinetics of terbutaline in chronic kidney diseaseAnders Bastiansen, Sarah Eggert, Erland Pedersen
Ugeskrift for Laeger|August 18, 2020
[Snakebites]Sarah Eggert, Jesper Kjærgaard, Anja Poulsen
Expert Opinion on Pharmacotherapy|February 24, 2018
Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatideSarah Eggert, Esther Zimmermann, Kamilla Begtrup
BMC Geriatrics|September 1, 2019
An augmented prescribed exercise program (APEP) to improve mobility of older acute medical patients - a randomized, controlled pilot and feasibility trialTobias Braun, Christian Grüneberg, Kirsten Süßmilch, et al.
Diabetes, Obesity & Metabolism|February 15, 2019
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetesAthena Philis-Tsimikas, Liana K Billings, Robert Busch, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
European Journal of Clinical Pharmacology|August 1, 2013
Pharmacokinetics of terbutaline in chronic kidney diseaseAnders Bastiansen, Sarah Eggert, Erland Pedersen
Ugeskrift for Laeger|August 18, 2020
[Snakebites]Sarah Eggert, Jesper Kjærgaard, Anja Poulsen
Expert Opinion on Pharmacotherapy|February 24, 2018
Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatideSarah Eggert, Esther Zimmermann, Kamilla Begtrup
BMC Geriatrics|September 1, 2019
An augmented prescribed exercise program (APEP) to improve mobility of older acute medical patients - a randomized, controlled pilot and feasibility trialTobias Braun, Christian Grüneberg, Kirsten Süßmilch, et al.
Diabetes, Obesity & Metabolism|February 15, 2019
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetesAthena Philis-Tsimikas, Liana K Billings, Robert Busch, et al.
Pageof 1